Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 43.75
Bid: 43.50
Ask: 44.00
Change: 0.75 (1.74%)
Spread: 0.50 (1.149%)
Open: 43.10
High: 44.00
Low: 43.10
Prev. Close: 43.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Avacta plans fundraise to fund clinical development

Wed, 28th Feb 2024 20:31

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Substrate Artificial Inteligence SA - Madrid-based incubator of companies providing artificial intelligence products and services in fintech, agritech, energy, human resources, and health sectors - Issues trading update to December 31. Expects 2023 revenue of EUR13.4 million, nearly three times 2022's EUR4.8 million. But, predicts adjusted loss before interest, tax, depreciation and amortisation widens to EUR4.1 million from EUR2.0 million. Says this reflects expenses made in the development of artificial intelligence products, costs associated with the listing of classes A and B shares into the Access segment of the AQSE Growth Market, and the acquisition of companies.

----------

Avacta Group PLC - Wetherby, England-based life sciences company developing oncology drugs and diagnostics - Plans to raise GBP13.8 million via placing and subscription at 50 pence per share. In addition, proposes to raise further GBP6.2 million via a conditional placing and GBP6.8 million by a retail offer. Proceeds to be used to initiate and progress the dose expansion and Phase 2 efficacy studies for its lead pre|CISIONTM clinical programme, AVA6000, as well as for general working capital until the end of 2025.

----------

SkinBioTherapeutics PLC - Newcastle, England-based life science company focused on skin health - Receives conversion notice on February 20 from Macquarie Bank Ltd for GBP80,000 of convertible bonds from the GBP5.0 million convertible bond facility announced on January 25. Further, plans to seek alternative financing options for its inorganic acquisition strategy, rather than drawing upon the facility any further.

----------

Beacon Rise Holdings PLC - acquisition company - Notes resolution at today's emergency general meeting was backed by 100% of shareholders. Explains vote extends time frame for Beacon Rise to pursue a suitable acquisition target for a further 12 months, to March 24, 2025.

----------

Downing Strategic Micro-Cap IT PLC - London-based investment trust - At the general meeting held Wednesday, announces the ordinary resolution relating to the adoption of the new investment policy was duly passed by shareholders. Around 87% of shareholders supported the motion.

----------

Beacon Energy PLC - Isle of Man-registered oil and gas company - Plans to raise GBP2.6 million via placing and retail offer at 0.05 pence per share. Explains the placing will be effected by way of an accelerated bookbuild. Proceeds to be used for further drilling, payment of outstanding costs and general working capital. States cash resources at February 16 totalled EUR1.2 million. Notes due to

delays during the drilling of the SCHB-2(2.) well, the company has an outstanding payables position due to a small number of contractors. Of this, around EUR1.1 million is due prior to the end of April with the balance of around EUR1.4 million due between May and August and expected to be funded from production post side-track. Beacon Energy expects to deliver operating cash flows during 2024 of around EUR40,000, EUR300,000, EUR800,000 and EUR1.3 million per month, at flow rates of 150, 300, 600 and 900 barrels of oil per day.

----------

Asian Energy Impact Trust PLC - investment company focused on sustainable energy infrastructure projects - Notes significant minority vote at Wednesday's general meeting, just over 20%, against resolutions 1, 2 and 3. Pledges to continue to seek to engage with shareholders to discuss any views they may have and will take into account any feedback around their concerns. Vote 1 was to receive the 2022 annual report and accounts of the company. Vote 2 to approve the directors' remuneration report. Vote 3 was to approve the directors' remuneration policy.

----------

Contango Holdings PLC - Holds 70% interest in the Muchesu mine in Zimbabwe - Reports pretax loss in the six months to November 30 of GBP1.4 million, narrowed from GBP1.8 million the year prior. Basic and diluted loss per share totalled 0.27p, compared to 0.55p. Administrative fees and other expenses fall to GBP879,951 from GBP1.3 million.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Jun 2021 20:24

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

TRADING UPDATES: CML plans AIM move; IronRidge to demerge gold assets

Read more
1 Jun 2021 11:16

Avacta confident despite filing delay for Covid-19 antigen test

(Sharecast News) - Diagnostics and cancer therapies developer Avacta Group updated the market on its CE-mark submission for its 'AffiDX' SARS-CoV-2 antigen lateral flow test for professional use.

Read more
28 May 2021 11:29

Avacta still waiting on response from UK regulator over Covid test

Avacta still waiting on response from UK regulator over Covid test

Read more
28 May 2021 07:29

Avacta still waiting on MHRA approval for Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group responded to speculation around the CE-mark submission for its SARS-CoV-2 antigen lateral flow test on Friday.

Read more
10 May 2021 11:13

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

IN BRIEF: Avacta to sell Covid-19 test in UK in "coming days"

Read more
22 Apr 2021 12:17

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Avacta sees Covid-19 tests driving earnings after reporting 2020 loss

Read more
20 Apr 2021 15:18

Avacta reports positive data for Covid-19 test product

(Sharecast News) - Diagnostics and cancer therapies developer Avacta announced positive data from the clinical validation of its 'AffiDX' SARS-CoV-2 antigen lateral flow test on Tuesday.

Read more
20 Apr 2021 12:17

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

IN BRIEF: Avacta's rapid Covid-19 test is 98% sensitive in trial

Read more
20 Apr 2021 11:35

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

AIM WINNERS & LOSERS: Warpaint tops outlook; Avacta's Covid test works

Read more
15 Apr 2021 14:56

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
6 Apr 2021 13:53

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

IN BRIEF: Avacta in global Affimer distribution agreement with Abcam

Read more
6 Apr 2021 11:03

Avacta signs global distribution deal with Abcam

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a global distribution agreement with Abcam, it announced on Tuesday, to sell its recently-developed SARS-CoV-2 research 'ELISA Affimer' reagents.

Read more
25 Mar 2021 15:57

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

EXECUTIVE CHANGES: Ten Entertainment, Emmerson chairs step down

Read more
9 Mar 2021 20:19

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

IN BRIEF: Avacta Group signs diagnostic licensing deal with Biokit

Read more
9 Mar 2021 11:08

Avacta enters licence deal with Werfen subsidiary Biokit

(Sharecast News) - Cancer therapy and diagnostics developer Avacta has entered into a licence agreement with Werfen subsidiary Biokit, it announced on Tuesday, to incorporate 'Affimer' reagents into a Biokit in-vitro diagnostic product.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.